Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аденомы гипофиза и синдром множественных неоплазий 1-го типа
Рожинская Л.Я., Ростомян Л.Г., Тюльпаков А.Н. Аденомы гипофиза и синдром множественных неоплазий 1-го типа. Consilium Medicum. 2013; 15 (4): 70–75.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Online Mendelian Inheritance in Man (OMIM), no. 131100; URL:www.ncbi.nlm.nih.gov/entrez/query.fcgi?db1/4OMIM.
2. Daly AF. Clinical and genetic features of familial pituitary adenomas. A.Daly, M.Jaffrain-Rea, A.Beckers. Horm Metab Res 2005; 37 (6): 347–54.
3. Verges B. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002; 87 (2): 457–65.
4. Daly AF. Clinical characterization of familial isolated pituitary adenomas. A.Daly, M.Jaffrain-Rea, A.Ciccarelli et al. J Clin Endocrinol Metab 2006; 91 (9): 3316–23.
5. Piecha G. Multiple endocrine neoplasia type 1. G.Piecha, J.Chudek, A.Wicek. Eur J Int Med 2008; 19: 99–103.
6. Brandi ML. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658–71.
7. Falchetti A. Multiple Endocrine Neoplasia Type I Variants and Phenocopies: More than a Nosological Issue? A.Falchetti, M.Brandi. J Clin Endocrinol Metab 2009; 94 (5): 1518–20.
8. Stalberg P. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab 2004; 89: 2326–37.
9. DeLellis RA et al. Pathology and genetics: Tumours of the endocrine organs. P.Kleihues, L.Sobin, eds. World Health Organization Classification of Tumours. Lyon (France): IARC Press 2004; 10: 257.
10. Beckers A. The treatment of sporadic versus MEN1-related pituitary adenomas. A.Beckers, D.Betea, H.Socin, A.Stevenaert. J Int Med 2003; 253: 599–605.
11. Gardner DG. Basic & Clinical Endocrinology. D.Gardner, D.Shoback, eds. Greenspan’s. 8th ed. New York: McGraw-Hill 2007.
12. Schussheim DH, Skarulis MC, Agarwal SK et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001; 12: 173–8.
13. O’Brien T, O’Riordan DS, Gharib H et al. Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. Neurosurgery 1996; 39: 273–8, discussion 278–9.
14. Farid RF, Buehler S, Russell NA et al. Prolactinomas in familial multiple endocrine neoplasia syndrome type, Relationship to HLA and carcinoid tumors. Am J Med 1980; 69: 874–80.
15. Burgess JR, Nord B, David R et al. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN 1). Clin Endocrinol (Oxf) 2000; 53: 205–11.
16. Dreijerink KMA et al. Acromegaly in a multiple endocrine neoplasia type 1 family with low penetrance of the disease. Eur J Endocrinology 2005; 153: 741–6.
17. Stratakis CA et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinology Metabol 2000; 85: 4776–80.
18. Eller-Vainicher C, Chiodini I, Battista C et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 2009; 24 (8): 1404–10.
19. Norton JA et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234 (4): 495–505.
20. Levy-Bohbot N et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 2004 (28): 1075–81.
21. Teh BT et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 1998; 228 (1): 99–105.
22. Callender GG, Rich ТА, Perrier ND. Multiple Endocrine Neoplasia Syndromes. Surg Clin N Am 2008; 88: 863–95.
23. Lairmore TC et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN1). Ann Surg 2004; 239 (5): 637–45; discussion: р. 645–537.
24. Owens M, Ellard S, Vaidya B. Analysis of gross deletions in the MEN1 gene in patients with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2008; 68: 350–4.
25. Peacock M, Bilezikian JP, Klassen PS et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 135–41.
26. Vestergaard P, Mosekilde L. Medical treatment of patients with primary hyperparathyroidism. Ugeskr Laeger 2009; 171 (33): 2284–7.
27. Triponez F et al. Is surgery beneficial for MEN-1 patients with small (=2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654–62.
28. Егоров А.В. и др. Аналоги соматостатина в диагностике и лечении нейроэндокринных опухолей. Анн. хирург. гепатол. 2009; 14 (4).
2. Daly AF. Clinical and genetic features of familial pituitary adenomas. A.Daly, M.Jaffrain-Rea, A.Beckers. Horm Metab Res 2005; 37 (6): 347–54.
3. Verges B. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002; 87 (2): 457–65.
4. Daly AF. Clinical characterization of familial isolated pituitary adenomas. A.Daly, M.Jaffrain-Rea, A.Ciccarelli et al. J Clin Endocrinol Metab 2006; 91 (9): 3316–23.
5. Piecha G. Multiple endocrine neoplasia type 1. G.Piecha, J.Chudek, A.Wicek. Eur J Int Med 2008; 19: 99–103.
6. Brandi ML. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658–71.
7. Falchetti A. Multiple Endocrine Neoplasia Type I Variants and Phenocopies: More than a Nosological Issue? A.Falchetti, M.Brandi. J Clin Endocrinol Metab 2009; 94 (5): 1518–20.
8. Stalberg P. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab 2004; 89: 2326–37.
9. DeLellis RA et al. Pathology and genetics: Tumours of the endocrine organs. P.Kleihues, L.Sobin, eds. World Health Organization Classification of Tumours. Lyon (France): IARC Press 2004; 10: 257.
10. Beckers A. The treatment of sporadic versus MEN1-related pituitary adenomas. A.Beckers, D.Betea, H.Socin, A.Stevenaert. J Int Med 2003; 253: 599–605.
11. Gardner DG. Basic & Clinical Endocrinology. D.Gardner, D.Shoback, eds. Greenspan’s. 8th ed. New York: McGraw-Hill 2007.
12. Schussheim DH, Skarulis MC, Agarwal SK et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001; 12: 173–8.
13. O’Brien T, O’Riordan DS, Gharib H et al. Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. Neurosurgery 1996; 39: 273–8, discussion 278–9.
14. Farid RF, Buehler S, Russell NA et al. Prolactinomas in familial multiple endocrine neoplasia syndrome type, Relationship to HLA and carcinoid tumors. Am J Med 1980; 69: 874–80.
15. Burgess JR, Nord B, David R et al. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN 1). Clin Endocrinol (Oxf) 2000; 53: 205–11.
16. Dreijerink KMA et al. Acromegaly in a multiple endocrine neoplasia type 1 family with low penetrance of the disease. Eur J Endocrinology 2005; 153: 741–6.
17. Stratakis CA et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinology Metabol 2000; 85: 4776–80.
18. Eller-Vainicher C, Chiodini I, Battista C et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 2009; 24 (8): 1404–10.
19. Norton JA et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234 (4): 495–505.
20. Levy-Bohbot N et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 2004 (28): 1075–81.
21. Teh BT et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 1998; 228 (1): 99–105.
22. Callender GG, Rich ТА, Perrier ND. Multiple Endocrine Neoplasia Syndromes. Surg Clin N Am 2008; 88: 863–95.
23. Lairmore TC et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN1). Ann Surg 2004; 239 (5): 637–45; discussion: р. 645–537.
24. Owens M, Ellard S, Vaidya B. Analysis of gross deletions in the MEN1 gene in patients with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2008; 68: 350–4.
25. Peacock M, Bilezikian JP, Klassen PS et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 135–41.
26. Vestergaard P, Mosekilde L. Medical treatment of patients with primary hyperparathyroidism. Ugeskr Laeger 2009; 171 (33): 2284–7.
27. Triponez F et al. Is surgery beneficial for MEN-1 patients with small (=2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654–62.
28. Егоров А.В. и др. Аналоги соматостатина в диагностике и лечении нейроэндокринных опухолей. Анн. хирург. гепатол. 2009; 14 (4).
Авторы
Л.Я.Рожинская, Л.Г.Ростомян, А.Н.Тюльпаков
ФГБУ Эндокринологический научный центр Минздрава РФ, Москва
ФГБУ Эндокринологический научный центр Минздрава РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.